Blood Disorder Treatment

Eltrombopag (REVOLADE FCT ALU) 30 Tablet

$760.00

REVOLADE FCT Tablet offers a valuable treatment option for patients with chronic immune thrombocytopenia (ITP) and chronic hepatitis C-related thrombocytopenia, providing effective platelet count management and reducing the risk of bleeding complications.

Strength	Choose an option25mg50mg
	Clear

Quantity

Eltrombopag (REVOLADE FCT ALU) 30 Tablet quantity

Add to cart

Sku:

N/A

Tag:

Eltrombopag (REVOLADE FCT ALU)

Description

REVLADAE FCT Tablet contains Eltrombopag in strengths of 25mg and 50mg, serving as a medication primarily prescribed for the treatment of thrombocytopenia (low platelet count) in patients with chronic immune thrombocytopenia (ITP) or chronic hepatitis C virus (HCV) infection.

Key Features:

• Thrombocytopenia Treatment: REVOLADE FCT Tablet is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP), a condition characterized by abnormally low platelet counts due to immune-mediated destruction of platelets.
• Eltrombopag Mechanism of Action: Eltrombopag, the active ingredient in REVOLADE, is a thrombopoietin receptor agonist that stimulates the production of platelets by binding to and activating the thrombopoietin receptor, thereby increasing platelet production and count.
• Chronic Hepatitis C Treatment: REVOLADE may also be used for the treatment of thrombocytopenia in patients with chronic hepatitis C virus (HCV) infection who are undergoing antiviral therapy, such as interferon-based regimens, where low platelet counts are a common side effect.
• Multiple Strengths: Available in two strengths (25mg and 50mg), allowing for individualized dosing based on factors such as platelet count, patient’s response to treatment, and tolerability.
• Fixed-Dose Tablet: REVOLADE FCT Tablet contains a fixed dose of Eltrombopag (25mg or 50mg) in each tablet, simplifying dosing and ensuring consistent medication delivery.
• Oral Administration: Administered orally, usually once daily, REVOLADE FCT Tablet offers convenient dosing for patients with thrombocytopenia, allowing them to take their medication at home.
• Clinical Efficacy: Clinical studies have demonstrated the efficacy of Eltrombopag in increasing platelet counts and reducing the risk of bleeding episodes in patients with chronic ITP and chronic hepatitis C-related thrombocytopenia.
• Potential Adverse Effects: Common side effects of REVOLADE may include headache, nausea, fatigue, diarrhea, and elevated liver enzymes. Patients should be monitored closely for adverse reactions and managed accordingly.
• Individualized Treatment Approach: The selection of REVOLADE as a treatment option for thrombocytopenia should be based on factors such as underlying disease etiology, platelet count, bleeding risk, patient’s overall health status, and treatment goals.

Additional information